SG Americas Securities
ZVRA icon

SG Americas Securities’s Zevra Therapeutics ZVRA Stock Holding History

SG Americas Securities’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,543
Closed -$121K – 3782
2025
Q4 		$121K Buy
+13,543
New +$128K ﹤0.01% 3145
2025
Q2 		– Sell
-18,186
Closed -$136K – 3692
2025
Q1 		$136K Sell
18,186
-5,314
-23% -$42.2K ﹤0.01% 2825
2024
Q4 		$196K Buy
23,500
+8,302
+55% +$70.9K ﹤0.01% 2174
2024
Q3 		$105K Buy
+15,198
New +$103K ﹤0.01% 3035
2024
Q2 		– Sell
-12,680
Closed -$74K – 3375
2024
Q1 		$74K Sell
12,680
-8,319
-40% -$51.1K ﹤0.01% 2642
2023
Q4 		$138K Buy
20,999
+6,175
+42% +$28.9K ﹤0.01% 2493
2023
Q3 		$71K Buy
+14,824
New +$74K ﹤0.01% 2876
2021
Q4 		– Sell
-13,689
Closed -$128K – 3864
2021
Q3 		$128K Buy
+13,689
New +$138K ﹤0.01% 3543
2016
Q2 		– Sell
-603
Closed -$140K – 3034
2016
Q1 		$140K Buy
+603
New +$146K ﹤0.01% 2420
2015
Q3 		– Sell
-451
Closed -$133K – 2787
2015
Q2 		$133K Buy
+451
New +$98.4K ﹤0.01% 2198

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

SG Americas Securities's ZVRA Position: Q1 2026 in Review

SG Americas Securities sold out of Zevra Therapeutics (ZVRA) in Q1 2026, closing a stake of 13,543 shares — an estimated $121K sold.

SG Americas Securities first reported a position in ZVRA in Q2 2015 and held it in 10 quarters. The position peaked at $196K in Q4 2024. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • SG Americas Securities reported no remaining Zevra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SG Americas Securities sold 13,543 Zevra Therapeutics shares in Q1 2026, an estimated $121K.
  • SG Americas Securities first reported a position in Zevra Therapeutics in Q2 2015 and held it in 10 quarters.
  • SG Americas Securities's Zevra Therapeutics position peaked at $196K in Q4 2024.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.